Repository logo
 

Molecular magnetic resonance imaging of myeloperoxidase activity identifies culprit lesions and predicts future atherothrombosis.

Published version
Peer-reviewed

Repository DOI


Change log

Abstract

AIMS: Unstable atherosclerotic plaques have increased activity of myeloperoxidase (MPO). We examined whether molecular magnetic resonance imaging (MRI) of intraplaque MPO activity predicts future atherothrombosis in rabbits and correlates with ruptured human atheroma. METHODS AND RESULTS: Plaque MPO activity was assessed in vivo in rabbits (n = 12) using the MPO-gadolinium (Gd) probe at 8 and 12 weeks after induction of atherosclerosis and before pharmacological triggering of atherothrombosis. Excised plaques were used to confirm MPO activity by liquid chromatography-tandem mass spectrometry (LC-MSMS) and to determine MPO distribution by histology. MPO activity was higher in plaques that caused post-trigger atherothrombosis than plaques that did not. Among the in vivo MRI metrics, the plaques' R1 relaxation rate after administration of MPO-Gd was the best predictor of atherothrombosis. MPO activity measured in human carotid endarterectomy specimens (n = 30) by MPO-Gd-enhanced MRI was correlated with in vivo patient MRI and histological plaque phenotyping, as well as LC-MSMS. MPO-Gd retention measured as the change in R1 relaxation from baseline was significantly greater in histologic and MRI-graded American Heart Association (AHA) type VI than type III-V plaques. This association was confirmed by comparing AHA grade to MPO activity determined by LC-MSMS. CONCLUSION: We show that elevated intraplaque MPO activity detected by molecular MRI employing MPO-Gd predicts future atherothrombosis in a rabbit model and detects ruptured human atheroma, strengthening the translational potential of this approach to prospectively detect high-risk atherosclerosis.

Description

Acknowledgements: We acknowledge the support of the Heart Research Institute mass spectrometry facility and the University of New South Wales Biological Resource Imaging Laboratory.


Funder: National Health & Medical Research Council of Australia; doi: https://doi.org/10.13039/501100000925


Funder: National Heart Foundation; doi: https://doi.org/10.13039/501100001516


Funder: University of New South Wales; doi: https://doi.org/10.13039/501100001773


Funder: NSW Department of Health


Funder: AstraZeneca; doi: https://doi.org/10.13039/100004325

Journal Title

Eur Heart J Imaging Methods Pract

Conference Name

Journal ISSN

2755-9637
2755-9637

Volume Title

2

Publisher

Oxford University Press (OUP)

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
British Heart Foundation (PG/2019/34897)